| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ... New England Journal of Medicine 351 (15), 1502-1512, 2004 | 7268 | 2004 |
| Alpha emitter radium-223 and survival in metastatic prostate cancer C Parker, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, SD Fosså, ... New England Journal of Medicine 369 (3), 213-223, 2013 | 3707 | 2013 |
| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 2099 | 2016 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2017* | 2021 |
| Abiraterone for prostate cancer not previously treated with hormone therapy ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ... New England Journal of Medicine 377 (4), 338-351, 2017 | 1767 | 2017 |
| Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ... The Lancet 392 (10162), 2353-2366, 2018 | 1102 | 2018 |
| Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer ND James, SA Hussain, E Hall, P Jenkins, J Tremlett, C Rawlings, ... New England Journal of Medicine 366 (16), 1477-1488, 2012 | 1012 | 2012 |
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor JCC Hu, RS Coffin, CJ Davis, NJ Graham, N Groves, PJ Guest, ... Clinical cancer research 12 (22), 6737-6747, 2006 | 662 | 2006 |
| Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind … O Sartor, R Coleman, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, ... The Lancet Oncology 15 (7), 738-746, 2014 | 560 | 2014 |
| Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019) ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ... European urology 67 (6), 1028-1038, 2015 | 521 | 2015 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 497* | 2021 |
| Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of … CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ... The lancet oncology 17 (2), 243-256, 2016 | 483 | 2016 |
| Required growth facilitators propel axon regeneration across complete spinal cord injury MA Anderson, TM O’Shea, JE Burda, Y Ao, SL Barlatey, AM Bernstein, ... Nature 561 (7723), 396-400, 2018 | 454 | 2018 |
| Confronting false discoveries in single-cell differential expression JW Squair, M Gautier, C Kathe, MA Anderson, ND James, TH Hutson, ... Nature communications 12 (1), 5692, 2021 | 431 | 2021 |
| Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review G Ploussard, S Daneshmand, JA Efstathiou, HW Herr, ND James, ... European urology 66 (1), 120-137, 2014 | 387 | 2014 |
| Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior … CN Sternberg, DP Petrylak, O Sartor, JA Witjes, T Demkow, JM Ferrero, ... Journal of clinical oncology 27 (32), 5431, 2009 | 386 | 2009 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 379 | 2015 |
| Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ... Annals of Oncology 30 (12), 1992-2003, 2019 | 371 | 2019 |
| Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta‐analysis SC Hillman, DJ McMullan, G Hall, FS Togneri, N James, EJ Maher, ... Ultrasound in Obstetrics & Gynecology 41 (6), 610-620, 2013 | 326 | 2013 |
| Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial CC Parker, NW Clarke, AD Cook, HG Kynaston, PM Petersen, C Catton, ... The Lancet 396 (10260), 1413-1421, 2020 | 299 | 2020 |
Matthew R SydesMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College在 ucl.ac.uk 的电子邮件经过验证
